See more : IBOKIN Co.,Ltd. (5699.T) Income Statement Analysis – Financial Results
Complete financial analysis of Amarin Corporation plc (AMRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amarin Corporation plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- American Commerce Solutions, Inc. (AACS) Income Statement Analysis – Financial Results
- Athlon Acquisition Corp. (SWETU) Income Statement Analysis – Financial Results
- Motorpoint Group Plc (MTPTF) Income Statement Analysis – Financial Results
- Kakatiya Cement Sugar and Industries Limited (KAKATCEM.BO) Income Statement Analysis – Financial Results
- IDEA Consultants,Inc. (9768.T) Income Statement Analysis – Financial Results
Amarin Corporation plc (AMRN)
About Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 306.91M | 369.19M | 583.19M | 614.06M | 429.76M | 229.21M | 181.10M | 130.08M | 81.76M | 54.20M | 26.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.37M | 500.00K | 500.00K | 1.02M | 7.37M | 65.51M | 53.77M | 17.55M | 11.22M | 19.00M | 24.30M | 21.50M | 29.10M | 18.70M | 14.70M |
| Cost of Revenue | 141.37M | 126.71M | 121.33M | 131.44M | 96.02M | 54.54M | 44.95M | 34.36M | 27.88M | 20.49M | 11.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 107.00K | 11.91M | 30.13M | 21.46M | 5.22M | 2.98M | 3.70M | 2.80M | 4.00M | 4.90M | 0.00 | 3.10M |
| Gross Profit | 165.54M | 242.48M | 461.86M | 482.62M | 333.74M | 174.67M | 136.15M | 95.72M | 53.88M | 33.72M | 14.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.37M | 500.00K | 500.00K | 910.00K | -4.55M | 35.38M | 32.32M | 12.33M | 8.24M | 15.30M | 21.50M | 17.50M | 24.20M | 18.70M | 11.60M |
| Gross Profit Ratio | 53.94% | 65.68% | 79.20% | 78.59% | 77.66% | 76.20% | 75.18% | 73.58% | 65.90% | 62.21% | 54.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 89.48% | -61.74% | 54.01% | 60.10% | 70.25% | 73.47% | 80.53% | 88.48% | 81.40% | 83.16% | 100.00% | 78.91% |
| Research & Development | 22.22M | 30.41M | 29.31M | 38.96M | 34.39M | 55.90M | 47.16M | 49.98M | 51.06M | 50.33M | 72.75M | 58.96M | 21.60M | 28.01M | 17.84M | 12.95M | 12.11M | 17.19M | 8.31M | 3.48M | 5.44M | 6.22M | 4.14M | 5.75M | 7.44M | 19.80M | 19.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 88.61M | 118.80M | 141.86M | 112.66M | 323.62M | 180.18M | 112.04M | 93.40M | 93.07M | 79.35M | 121.25M | 57.79M | 22.56M | 17.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 111.33M | 185.61M | 266.47M | 350.65M | 0.00 | 46.82M | 22.51M | 17.97M | 7.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 199.94M | 304.42M | 408.33M | 463.31M | 323.62M | 227.00M | 134.55M | 111.37M | 101.04M | 79.35M | 121.25M | 57.79M | 22.56M | 17.09M | 15.25M | 15.23M | 19.46M | 13.27M | 9.77M | 9.03M | 30.89M | 23.66M | 33.26M | 9.14M | 5.30M | 9.70M | 7.30M | 34.60M | 18.60M | 0.00 | 9.90M |
| Other Expenses | 10.97M | -740.00K | -302.00K | 104.00K | -75.00K | -326.00K | 74.00K | -482.00K | -228.00K | 3.73M | -1.19M | -427.00K | 0.00 | 0.00 | -2.16M | 0.00 | 9.17M | 674.00K | 676.00K | -510.00K | -2.05M | 39.24M | 0.00 | -1.00K | 2.32M | 2.60M | 2.50M | 1.20M | 1.00M | 0.00 | 600.00K |
| Operating Expenses | 233.13M | 334.83M | 437.64M | 502.27M | 358.02M | 282.90M | 181.71M | 161.35M | 152.10M | 129.67M | 194.00M | 116.75M | 44.16M | 45.10M | 30.93M | 28.18M | 40.73M | 31.13M | 18.76M | 12.00M | 34.27M | 69.12M | 37.40M | 14.89M | 15.05M | 32.10M | 29.60M | 35.80M | 19.60M | 0.00 | 10.50M |
| Cost & Expenses | 374.50M | 461.54M | 558.97M | 633.72M | 454.03M | 337.44M | 226.66M | 195.71M | 179.98M | 150.16M | 205.91M | 116.75M | 44.16M | 45.10M | 30.93M | 28.18M | 40.73M | 31.13M | 18.76M | 12.11M | 46.19M | 99.25M | 58.85M | 20.11M | 18.03M | 35.80M | 32.40M | 39.80M | 24.50M | 0.00 | 13.60M |
| Interest Income | 11.86M | 2.82M | 1.22M | 4.90M | 8.50M | 1.07M | 429.00K | 234.00K | 132.00K | 96.00K | 343.00K | 544.00K | 231.00K | 53.00K | 780.00K | 9.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.00K | 15.00K | 129.00K | 2.61M | 6.63M | 7.80M | 9.77M | 18.44M | 20.05M | 18.48M | 34.18M | 18.09M | 1.00K | 19.00K | 8.23M | 2.14M | 6.46M | 0.00 | 1.80M | 0.00 | 0.00 | 29.46M | 0.00 | 0.00 | 0.00 | 24.40M | 800.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.97M | 3.09M | 2.86M | 2.05M | 862.56K | 667.87K | 715.59K | 777.59K | 812.00K | 844.00K | 892.00K | 449.00K | 76.00K | 63.00K | 582.00K | 251.00K | 386.00K | 795.00K | 810.00K | 754.00K | 671.00K | 8.29M | 21.22M | 2.42M | 2.32M | 2.60M | 2.50M | 1.20M | 1.00M | 0.00 | 600.00K |
| EBITDA | -50.90M | -100.65M | 14.28M | -12.71M | -15.06M | -106.63M | -44.82M | -56.53M | -97.41M | -39.78M | -134.62M | -152.32M | -66.79M | -249.90M | -55.16M | -19.87M | -38.44M | -31.16M | -19.29M | -9.85M | -6.09M | -25.45M | 16.14M | -224.00K | -4.81M | -7.90M | -5.60M | -17.10M | 5.60M | 18.70M | 1.70M |
| EBITDA Ratio | -16.59% | -24.45% | 4.31% | -2.39% | -3.69% | -47.36% | -24.49% | -50.82% | -120.42% | -170.16% | -681.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -437.07% | -6,280.80% | -3,358.80% | -3,309.93% | -732.53% | 6.42% | 29.96% | -2.85% | -27.11% | -8.95% | -15.64% | -87.44% | 16.15% | 100.00% | 9.52% |
| Operating Income | -67.59M | -92.34M | 22.28M | -19.66M | -24.28M | -108.23M | -45.56M | -65.63M | -98.22M | -95.96M | -182.11M | -116.75M | -44.16M | -45.10M | -52.30M | -28.18M | -40.73M | -31.16M | -18.91M | -11.09M | -38.82M | -32.66M | -5.08M | -2.56M | -6.81M | -16.80M | -8.10M | -18.30M | 4.60M | 18.70M | 1.10M |
| Operating Income Ratio | -22.02% | -25.01% | 3.82% | -3.20% | -5.65% | -47.22% | -25.15% | -50.45% | -120.14% | -177.03% | -691.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -553.06% | -6,232.20% | -3,781.60% | -1,090.66% | -527.10% | -49.86% | -9.44% | -14.59% | -60.71% | -88.42% | -33.33% | -85.12% | 15.81% | 100.00% | 7.48% |
| Total Other Income/Expenses | 13.92M | 2.06M | 789.00K | 2.40M | 1.80M | -8.12M | -9.26M | -10.76M | -20.07M | 36.75M | 12.69M | -54.20M | -22.73M | -204.92M | -29.36M | 7.22M | -7.08M | 3.64M | -2.35M | 222.00K | 12.24M | -883.00K | -298.00K | 525.00K | -1.63M | -5.50M | -3.20M | 1.60M | 900.00K | 0.00 | 200.00K |
| Income Before Tax | -53.67M | -103.81M | 11.29M | -17.26M | -22.48M | -116.35M | -54.82M | -76.38M | -118.29M | -59.20M | -169.42M | -170.07M | -66.61M | -250.09M | -59.76M | -20.70M | -39.03M | -27.72M | -19.41M | 11.35M | -26.58M | -33.55M | -4.71M | -2.22M | -10.15M | -30.10M | -11.30M | -16.70M | 5.50M | 0.00 | 1.30M |
| Income Before Tax Ratio | -17.49% | -28.12% | 1.94% | -2.81% | -5.23% | -50.76% | -30.27% | -58.72% | -144.69% | -109.22% | -642.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -529.99% | -5,543.80% | -3,881.00% | 1,115.54% | -360.90% | -51.21% | -8.76% | -12.66% | -90.48% | -158.42% | -46.50% | -77.67% | 18.90% | 0.00% | 8.84% |
| Income Tax Expense | 5.44M | 2.00M | 3.56M | 745.00K | 164.00K | 96.00K | 13.05M | 9.97M | -3.09M | -2.84M | -3.19M | 9.12M | 2.52M | -501.00K | -440.00K | -674.00K | -837.00K | -799.00K | -698.00K | 7.33M | -7.36M | 3.54M | 412.00K | 342.00K | -27.00K | 100.00K | 600.00K | -1.10M | 1.40M | 15.90M | 500.00K |
| Net Income | -59.11M | -105.80M | 7.73M | -18.00M | -22.65M | -116.45M | -67.87M | -86.35M | -115.20M | -56.36M | -166.23M | -179.18M | -69.13M | -249.59M | -59.32M | -20.02M | -38.20M | -26.92M | -18.71M | 4.01M | -19.22M | -37.08M | -4.76M | 2.36M | 4.37M | -28.80M | -7.70M | -15.60M | 4.10M | 2.80M | 900.00K |
| Net Income Ratio | -19.26% | -28.66% | 1.33% | -2.93% | -5.27% | -50.80% | -37.47% | -66.38% | -140.91% | -103.99% | -630.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -518.63% | -5,384.00% | -3,741.40% | 394.49% | -261.02% | -56.61% | -8.85% | 13.43% | 38.96% | -151.58% | -31.69% | -72.56% | 14.09% | 14.97% | 6.12% |
| EPS | -0.15 | -0.26 | 0.02 | -0.05 | -0.07 | -0.39 | -0.25 | -0.41 | -0.64 | -0.32 | -1.03 | -1.24 | -0.53 | -2.49 | -1.40 | -0.91 | -4.08 | -3.35 | -4.63 | 1.72 | -11.24 | -39.71 | -0.67 | 6.42 | 2.90 | -19.29 | -52.00 | -110.00 | 31.00 | 20.00 | 8.00 |
| EPS Diluted | -0.15 | -0.26 | 0.02 | -0.05 | -0.07 | -0.39 | -0.25 | -0.41 | -0.64 | -0.32 | -0.99 | -1.24 | -0.53 | -2.49 | -1.40 | -0.91 | -4.08 | -3.35 | -4.63 | 1.72 | -11.24 | -39.71 | -0.40 | 3.02 | 2.90 | -19.29 | -52.00 | -110.00 | 31.00 | 20.00 | 8.00 |
| Weighted Avg Shares Out | 407.66M | 401.16M | 395.99M | 381.76M | 342.54M | 297.24M | 270.65M | 210.61M | 179.59M | 173.72M | 161.02M | 144.02M | 130.25M | 100.24M | 42.42M | 22.06M | 9.37M | 8.03M | 4.04M | 1.79M | 1.71M | 933.77K | 7.12M | 149.89K | 1.50M | 1.49M | 148.08K | 141.82K | 132.26K | 140.00K | 112.50K |
| Weighted Avg Shares Out (Dil) | 407.66M | 401.16M | 402.48M | 381.76M | 342.54M | 297.24M | 270.65M | 211.87M | 180.65M | 173.82M | 167.07M | 144.02M | 130.25M | 100.24M | 42.42M | 22.06M | 9.37M | 8.03M | 4.04M | 1.79M | 1.71M | 933.77K | 12.04M | 842.09K | 1.50M | 1.49M | 148.08K | 141.82K | 132.26K | 140.00K | 112.50K |
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –-
Amarin stock falls after CEO Mikhail resigns, company disputes CEO asserting of entitlement to severance
Shares of Amarin Corp. AMRN, -5.19% rose dropped 5.5% toward a near three-month low in premarket trading Friday, after the biopharmaceutical company focused on therapies for cardiovascular health disclosed that Chief Executive Karim Mikhail has resigned, effective immediately, after about...
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
New Amarin Board Believes the Company Will Thrive with Proper Stewardship
Amarin Announces Board Departures
DUBLIN, Ireland and BRIDGEWATER. N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that, in the interest of the Company to avoid further proxy contests, all seven independent non-Sarissa board members:...
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
--In Vitro Data Presentations Support Antithrombotic and Antioxidant Effects of EPA Compared with DHA, No Impact of Mineral Oil on Rates of LDL Oxidation -–
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
--Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without Increased Bleeding-- --Analysis Builds on Consistently Demonstrated Positive Outcomes for VASCEPA/VAZKEPA Across Sub-Populations in REDUCE-IT, Including in...
Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates
Amarin Corporation's (AMRN) fourth-quarter 2022 earnings and revenues beat estimates; Vascepa sales decline.
Penny Stocks To Buy: 5 To Watch Before Next Week
Penny stocks to watch this week. The post Penny Stocks To Buy: 5 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Amarin Corporation plc (AMRN) Q4 2022 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN ) Q4 2022 Results Conference Call March 1, 2023 8:00 AM ET Company Participants Lisa DeFrancesco - Senior Vice President, Corporate Affairs and Investor Relations Karim Mikhail - President and Chief Executive Officer Tom Reilly -...
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-- Company Delivers Positive Free Cash Flow in Fourth Quarter 2022 Following U.S. Revenue Stabilization -- -- Previously Announced Cost Savings Program On-Track to Exceed $100 Million Target --
Source: https://incomestatements.info
Category: Stock Reports